Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Public ClinicalTrials.gov record NCT06211036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Study identification
- NCT ID
- NCT06211036
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 563 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 5, 2024 (Actual)
- Primary completion
- Jul 5, 2027 (Estimated)
- Completion
- Sep 30, 2028 (Estimated)
- Last update posted
- Dec 17, 2025
2024 – 2028
United States locations
- U.S. sites
- 37
- U.S. states
- 24
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Infirmary Cancer Center | Mobile | Alabama | 36607 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | — |
| University Cancer and Blood Center LLC | Athens | Georgia | 30607 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| University of Illinois Chicago | Chicago | Illinois | 60612 | — |
| Franciscan Health Indianapolis | Indianapolis | Indiana | 46237 | — |
| Our Lady of the Lake Cancer Institute | Baton Rouge | Louisiana | 70808 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Allina Health System dba Allina Health Cancer Institute | Saint Paul | Minnesota | 55102 | — |
| Oncology Hematology Associates | Springfield | Missouri | 65807 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Montefiore Medical Center - Bronx | The Bronx | New York | 10461 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Oncology Hematology Care Incorporated | Cincinnati | Ohio | 45242 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Oncology Associates of Oregon, PC | Eugene | Oregon | 97401 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Baptist Cancer Center Memphis Thoracic | Memphis | Tennessee | 38120 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Dallas Fort Worth | Dallas | Texas | 75246 | — |
| US Oncology Research Investigational Products Center | Dallas | Texas | 75246 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Oncology Associates | Newport News | Virginia | 23606 | — |
| Virginia Commonwealth University Massey Cancer Center | Richmond | Virginia | 23298 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| The Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 182 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06211036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06211036 live on ClinicalTrials.gov.